Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B/pp65 vaccination using a lymphocytic choriomeningitis virus vector

Clinical and Vaccine Immunology

Volumn 24, Issue 1, 2017, Pages

  Schleiss, Mark R ^a   Berka, Ursula ^b   Watson, Elizabeth ^b   Aistleithner, Mario ^b   Kiefmann, Bettina ^b   Mangeat, Bastien ^c   Swanson, Elizabeth C ^a   Gillis, Peter A ^a   Hernandez Alvarado, Nelmary ^a   Fernández Alarcón, Claudia ^a   Zabeli, Jason C ^a   Pinschewer, Daniel D ^c   Lilj, Anders E ^a,b   Schwendinger, Michael ^b   Guirakhoo, Farshad ^b   Monath, Thomas P ^b   Orlinger, Klaus K ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HOOKIPA BIOTECH AG   (Austria)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Congenital cytomegalovirus; Cytomegalovirus; Fetal infection; Live vector vaccines; Lymphocytic choriomeningitis virus; Placental immunology

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; FREUND ADJUVANT; LYMPHOCYTIC CHORIOMENINGITIS VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; CYTOMEGALOVIRUS VACCINE; DRUG CARRIER; GLYCOPROTEIN B, SIMPLEXVIRUS; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PHOSPHOPROTEIN; RECOMBINANT VACCINE; VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIREMIA; ANIMAL; BLOOD; C57BL MOUSE; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODEL; GENETICS; GUINEA PIG; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GUINEA PIGS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE, INBRED C57BL; PHOSPHOPROTEINS; T-LYMPHOCYTES; VACCINES, COMBINED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 85011298960     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.0030016     Document Type: Article

References (44)

1. Griffiths P, Baraniak I, Reeves M. 2015. The pathogenesis of human cytomegalovirus. J Pathol 235:288-297. https://doi.org/10.1002/ path.4437.
2. Boeckh M, Geballe AP. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121:1673-1680. https://doi.org/10.1172/ JCI45449.
3. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. 2004. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39:233-239. https:// doi.org/10.1086/421999.
4. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33. https://doi.org/ 10.1016/j.molmed.2005.11.006.
5. Sung H, Schleiss MR. 2010. Update on the current status of cytomega-lovirus vaccines. Expert Rev Vaccines 9:1303-1314. https://doi.org/ 10.1586/erv.10.125.
6. Fu TM, An Z, Wang D. 2014. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32:2525-2533. https://doi.org/10.1016/j.vaccine.2014.03.057.
7. McVoy MA. 2013. Cytomegalovirus vaccines. Clin Infect Dis 57(Suppl 4):S196-S199. https://doi.org/10.1093/cid/cit587.
8. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. 2005. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685. https://doi.org/10.1084/jem.20050882.
9. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199. https://doi.org/ 10.1056/NEJMoa0804749.
10. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, Turley CB, Stanberry LR, Patel SM, McNeal MM, Pichon S, Amegashie C, Bellamy AR. 2016. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine 34:313-319. https://doi.org/10.1016/j.vaccine.2015.11.056.
11. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. https://doi.org/10.1016/ S0140-6736(11)60136-0.
12. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. 2012. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Infect Dis 12:290-299. https://doi.org/ 10.1016/S1473-3099(11)70344-9.
13. Gönczöl E, Berensci K, Pincus S, Endresz V, Méric C, Paoletti E, Plotkin SA. 1995. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080-1085.
14. Berencsi K, Gyulai Z, Gönczöl E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S, Plotkin S. 2001. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183:1171-1179.
15. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD. 2009. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484-493. https://doi.org/10.1016/j.vaccine.2009.09.135.
16. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, Newell M, Tran E, Ortiz J, La Rosa C, Herrmann A, Longmate J, Chakraborty R, Barry PA, Diamond DJ. 2014. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524. https://doi.org/10.1371/journal.ppat.1004524.
17. Bia FJ, Griffith BP, Fong CK, Hsiung GD. 1983. Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 5:177-195. https://doi.org/10.1093/clinids/5.2.177.
18. Schleiss MR. 2008. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. J Clin Virol 41:224-230. https:// doi.org/10.1016/j.jcv.2007.10.008.
19. Schleiss MR. 2013. Developing a vaccine against congenital cytomegalovirus (CMV) infection: what have we learned from animal models? Where should we go next? Future Virol 8:1161-1182. https://doi.org/ 10.2217/fvi.13.016.
20. Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF. 2007. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195: 789-798. https://doi.org/10.1086/511982.
21. Swanson EC, Gillis P, Hernandez-Alvarado N, Fernández-Alarcón C, Schmit M, Zabeli JC, Wussow F, Diamond DJ, Schleiss MR. 2015. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality. Vaccine 33:4013-4018. https://doi.org/10.1016/j.vaccine .2015.06.019.
22. Flatz L, Bergthaler A, de la Torre JC, Pinschewer DD. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A 103:4663-4668. https://doi.org/10.1073/pnas .0600652103.
23. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD. 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16:339-345. https://doi.org/10.1038/ nm.2104.
24. Tugizov S, Maidji E, Xiao J, Zheng Z, Pereira L. 1998. Human cytomegalovirus glycoprotein B contains autonomous determinants for vectorial targeting to apical membranes of polarized epithelial cells. J Virol 72: 7374-7386.
25. Radsak K, Eickmann M, Mockenhaupt T, Bogner E, Kern H, Eis-Hübinger A, Reschke M. 1996. Retrieval of human cytomegalovirus glycoprotein B from the infected cell surface for virus envelopment. Arch Virol 141: 557-572. https://doi.org/10.1007/BF01718317.
26. Tugizov S, Maidji E, Xiao J, Pereira L. 1999. An acidic cluster in the cytosolic domain of human cytomegalovirus glycoprotein B is a signal for endocytosis from the plasma membrane. J Virol 73:8677-8688.
27. Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, Rasmussen L, Merigan TC, Pachl C. 1988. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167: 207-225. https://doi.org/10.1016/0042-6822(88)90071-2.
28. Nowak B, Gmeiner A, Sarnow P, Levine AJ, Fleckenstein B. 1984. Physical mapping of human cytomegalovirus genes: identification of DNA sequences coding for a virion phosphoprotein of 71 kDa and a viral 65-kDa polypeptide. Virology 134:91-102. https://doi.org/10.1016/0042 -6822(84)90275-7.
29. Fox CB, Haensler J. 2013. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 12: 747-758. https://doi.org/10.1586/14760584.2013.811188.
30. Britt WJ, Vugler L, Stephens EB. 1988. Induction of complementdependent and -independent neutralizing antibodies by recombinantderived human cytomegalovirus gp55-116 (gB). J Virol 62:3309-3318.
31. Selinsky C, Luke C, Wloch M, Geall A, Hermanson G, Kaslow D, Evans T. 2005. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 1:16-23. https:// doi.org/10.4161/hv.1.1.1335.
32. Gillis PA, Hernandez-Alvarado N, Gnanandarajah JS, Wussow F, Diamond DJ, Schleiss MR. 2014. Development of a novel, guinea pigspecific IFN-gamma; ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-3970. https://doi.org/10.1016/ j.vaccine.2014.05.011.
33. Swanson EC, Schleiss MR. 2013. Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr Clin North Am 60: 335-349. https://doi.org/10.1016/j.pcl.2012.12.008.
34. Beam E, Dioverti V, Razonable RR. 2014. Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities. Curr Infect Dis Rep 16:419. https://doi.org/10.1007/ s11908-014-0419-8.
35. Boeckh M, Gilbert PB. 2016. Search continues for a CMV vaccine for transplant recipients. Lancet Haematol 3:e58-359. https://doi.org/ 10.1016/S2352-3026(15)00286-0.
36. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. 2010. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386-389. https://doi.org/10.1086/649903.
37. Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI. 2016. Replicationdefective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine 34:1993-1999. https://doi.org/10.1016/j.vaccine.2016.03.005.
38. Cui X, Lee R, Adler SP, McVoy MA. 2013. Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol Methods 192: 44-50. https://doi.org/10.1016/j.jviromet.2013.04.015.
39. Cui X, Meza BP, Adler SP, McVoy MA. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766. https://doi.org/10.1016/j.vaccine.2008 .07.092.
40. Saccoccio FM, Gallagher MK, Adler SP, McVoy MA. 2011. Neutralizing activity of saliva against cytomegalovirus. Clin Vaccin Immunol 18: 1536-1542. https://doi.org/10.1128/CVI.05128-11.
41. Saccoccio FM, Sauer AL, Cui X, Armstrong AE, Habib el-SE, Johnson DC, Ryckman BJ, Klingelhutz AJ, Adler SP, McVoy MA. 2011. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 29:2705-2711. https://doi.org/10.1016/j.vaccine.2011.01.079.
42. Shedlock DJ, Talbott KT, Wu SJ, Wilson CM, Muthumani K, Boyer JD, Sardesai NY, Awasthi S, Weiner DB. 2012. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother 8:1668-1681. https:// doi.org/10.4161/hv.22447.
43. Schleiss MR, Bierle CJ, Swanson EC, McVoy MA, Wang JB, Al-Mahdi Z, Geballe AP. 2015. Vaccination with a live attenuated cytomegalovirus devoid of a protein kinase R inhibitory gene results in reduced maternal viremia and improved pregnancy outcome in a guinea pig congenital infection model. J Virol 89:9727-9738. https://doi.org/ 10.1128/JVI.01419-15.
44. Schäfer H, Kliem G, Kropp B, Burger R. 2007. Monoclonal antibodies to guinea pig interferon-gamma: tools for cytokine detection and neutralization. J Immunol Methods 328:106-117. https://doi.org/10.1016/ j.jim.2007.08.012.